PHASE II TRIAL OF PHENYLACETIC ACID FOR RECURRENT MALIGNANT GILOMA SWOG9443

这是苯乙酸治疗复发性恶性肿瘤的II期试验。 北美脑瘤联盟正在进行的胶质瘤 (NABTC)和西南肿瘤学小组(SWOG)。预计 匹兹堡癌症大学将有10名患者参加这项研究 研究所。苯乙酸酯(PAA)的起始剂量为400 毫克/公斤/天(理想体重)，使用持续静脉输液， 14天，然后休息14天。重复14天的输液将是 给予，然后休息14天。

This is a Phase II trial of phenylacetic acid for recurrent malignant glioma being conducted by the North American Brain Tumor consortitum (NABTC) and the Southwest Oncology Group (SWOG). It is anticipated that 10 patients will enter this study at the University of Pittsburgh Cancer Institute. Phenylacetate (PAA) will be given at a starting dose of 400 mg/kg/day (Ideal Body Weight) using a continous intravenous infusion, for 14 days, followed by a 14 day rest. A repeat 14 day infusion will be given, followed by a 14 day rest.